REVIEWS

1909  Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
      Basel Sitohy, Janice A. Nagy, and Harold F. Dvorak

1915  Nodal Expression and Detection in Cancer: Experience and Challenges
      Luigi Strizzi, Katharine M. Hardy, Dawn A. Kirschmann, Lars Ahrlund-Richter, and Mary J.C. Hendrix

PRIORITY REPORTS

1921  Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

1929  The Mixed Lineage Leukemia (MLL) Fusion–Associated Gene AFI Promotes CD133 Transcription
      Anthony B. Mak, Allison M.L. Nixon, and Jason Moffat

INTEGRATED SYSTEMS AND TECHNOLOGIES

1935  Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer
      Lynn M. Amon, Sharon J. Pitteri, Christopher I. Li, Martin McIntosh, Jon J. Ladil, Mary Disis, Peggy Porter, Chee Hong Wong, Qing Zhang, Paul Lampe, Ross L. Prentice, and Samir M. Hanash
      Précis: Through a combination of mass spectrometry and gene set analysis, glycolysis pathway proteins are identified in the blood of breast cancer patients prior to diagnosis, suggesting that these proteins may serve as circulating biomarkers and potentially complement mammography in breast cancer screening.

MICROENVIRONMENT AND IMMUNOLOGY

1943  Dermatan Sulfate Is Involved in the Tumorigenic Properties of Esophagus Squamous Cell Carcinoma
      Martin A. Thelin, Katrin J. Svensson, Xiaofeng Shi, Mariam Bagher, Jakob Axelsson, Anna Isinger-Ekstrand, Toin H. van Kuppevelt, Jan Johansson, Mef Nilbert, Joseph Zaia, Mattias Belting, Marco Maccarana, and Anders Malmström
      Précis: Expression and structure of an extracellular proteoglycan that is altered widely in esophageal cancer is responsible for driving invasive cell migration, suggesting a novel targeting approach to attack this deadly cancer.

1953  Genetic Deficiency in Plasma Protein HRG Enhances Tumor Growth and Metastasis by Exacerbating Immune Escape and Vessel Abnormalization
      Précis: Findings establish an important link between deficiency of a highly expressed plasma protein and tumor progression via activation of protumoral macrophages and immune suppression.
**MOLECULAR AND CELLULAR PATHOBIOLOGY**

**1964**

**Densely Granulated Murine NK Cells Eradicate Large Solid Tumors**
Rebecca B. Liu, Boris Engels, Ainhoa Arina, Karin Schreiber, Elizabeth Hyje, Andrea Schietinger, David C. Binder, Eric Butz, Thomas Krausz, Donald A. Roweley, Bana Jabri, and Hans Schreiber

**Précis:** If present, high levels of a cytokine implicated in immune memory in the tumor microenvironment will promote the accumulation of densely granulated natural killer cells that are capable of eradicating large solid tumors.

**1975**

**Increased CD8⁺ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells**
Shuai Tang, Miranda L. Moore, Jason M. Grayson, and Purnima Dubey

**Précis:** Findings show that androgen ablation expands both the effector and inhibitory arms of the immune response to tumors, resulting in only a transient enhancement of immune function.

**1986**

**A Potent Vaccination Strategy That Circumvents Lymphodepletion for Effective Antitumor Adoptive T-cell Therapy**
Hyun-II Cho, Eduardo Reyes-Vargas, Julio C. Delgado, and Esteban Celis

**Précis:** Findings suggest a simple, effective strategy to improve adoptive T-cell therapy for melanoma treatment that avoids complications associated with lymphodepletion and high-dose interleukin-2 treatment.

**2006**

**INT6/EIF3E Interacts with ATM and Is Required for Proper Execution of the DNA Damage Response in Human Cells**
Christelle Morris, Nozomi Tomimatsu, Derek J. Richard, David Cluet, Sandeep Burma, Kum Kum Khanna, and Pierre Jalinot

**Précis:** Findings reveal a novel and important function in DNA repair that may be closely involved in the onset of breast cancers initiated by defects in the DNA damage response.

**PREVENTION AND EPIDEMIOLOGY**

**2017**

**FGFR2 Isoforms Support Epithelial–Stromal Interactions in Thyroid Cancer Progression**
Miao Guo, Wei Liu, Stefano Serra, Sylvia L. Asa, and Shereen Ezzat

**Précis:** This study highlights the importance of the context in the tumor of the regulatory properties of different growth factor receptor isoforms by illustrating how alternative splicing can confer different functions depending on whether the receptor is expressed in tumor versus tumor stromal cells.

**2028**

**Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age**
Christopher I. Li, Elisabeth F. Beaber, Mei Tzu Chen Tang, Peggy L. Porter, Janet R. Daling, and Kathleen E. Malone

**Précis:** The most common injectable contraceptive may increase breast cancer risk among young women who use it.

**Characterization of Gene–Environment Interactions for Colorectal Cancer Susceptibility Loci**

**Précis:** This study reveals a colon cancer risk locus variant that appears to be modified by vegetable consumption, motivating further work to elucidate environmental influences on cancer susceptibility genes.
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine, Lorraine Mooney, Elaine Kilgour, Andrew P. Thomas, Katherine Al-Kadhimi, Sarah Beck, Claire Rooney, Tanya Coleman, Dawn Baker, Martine J. Mellor, A. Nigel Brooks, and Teresa Klimowska

Précis: A potent and highly selective small-molecule inhibitor may offer a broad-based approach for treatment of many kinds of tumors that involve activation of the fibroblast growth factor receptor.

Intratracheal Administration of a Nanoparticle-Based Therapy with the Angiotensin II Type 2 Receptor Gene Attenuates Lung Cancer Growth
Atsushi Kawabata, Abdulgader Baoum, Naomi Ohta, Stephanie Jacquez, Gwi-Moon Seo, Cory Berkland, and Masaaki Tamura

Précis: Findings offer a preclinical validation for a nontoxic cationic, peptide-based nanoparticle vector that can deliver genes via the trachea for effective treatment of lung cancers.

Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity

Précis: Genetic predisposition studies not only can identify mechanisms of cancer susceptibility but also can reveal therapeutically relevant oncogenic vulnerabilities that may be exploitable clinically.

Deficiency in Mammalian Histone H2B Ubiquitin Ligase BRE1 (Rnf20/Rnf40) Leads to Replication Stress and Chromosomal Instability
Sophia B. Chernikova, Olga V. Razorenova, John P. Higgins, Brock J. Sischy, Monica Nicolau, Jennifer A. Dorth, Diana A. Chernikova, Shirley Kwok, James D. Brooks, Susan M. Bailey, John C. Game, and Martin Brown

Précis: Genomic instability caused by deficiency in a histone ubiquitin ligase may be an important initial step in acquisition of an invasive phenotype by an early-stage noninvasive tumor.

Type I and II IFNs Inhibit Merkel Cell Carcinoma via Modulation of the Merkel Cell Polyomavirus T Antigens
Christopher Willmes, Christian Adam, Miriam Alh, Lena Volkert, Roland Houben, Jürgen C. Becker, and David Schrama

Précis: Merkel cell carcinoma, a rare but highly aggressive skin cancer driven by a polyomavirus tumor antigen, may be susceptible to IFN therapies found to modulate the antigen's expression.
CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency

Adam S. Adler, Mark L. McCleland, Tom Truong, Shari Lau, Zora Modrusan, Tim M. Soukup, Merone Roose-Girma, Elizabeth M. Blackwood, and Ron Firestein

Précis: Therapeutic targeting of the cyclin-dependent kinase CDK8 may specifically blunt stem-like properties in cancer cells.

Expression of a Truncated Active Form of VDAC1 in Lung Cancer Associates with Hypoxic Cell Survival and Correlates with Progression to Chemotherapy Resistance

M. Christiane Brahimi-Horn, Danya Ben-Hail, Marius Ilie, Pierre Gounon, Matthieu Rouleau, Véronique Hofman, Jérôme Doyen, Bernard Mari, Varda Shoshan-Barmatz, Paul Hofman, Jacques Pouysségur, and Nathalie M. Mazure

Précis: Blockade of a mitochondria anion channel may improve response to lung cancer therapy by restoring apoptotic sensitivity and circumventing chemoresistance in hypoxic tumor cells.

ABOUT THE COVER

The HIV-1 TAT peptide was dimerized and used to formulate a nanoparticle vector (dTAT NP) to leverage efficient tumor-targeted gene delivery following intratracheal administration. In vitro expression efficiency for dTAT NP–encapsulated luciferase or angiotensin II type 2 receptor (AT2R) plasmid DNA (pDNA) revealed effective pDNA transfection with negligible cytotoxicity. In orthotopic tumor grafts, immunohistochemical analysis confirmed that dTAT NP successfully delivered pDNA to the tumor, and gene expression in tumor tissues persisted at least 14 days after intratracheal administration. Bolus administration of dTAT NP–encapsulated AT2R or TRAIL pDNA, both endogenous apoptosis inducers, markedly attenuated tumor growth. For details, see article by Kawabata and colleagues on page 2057.